Novartis’s Gilenya Loses Market Share After Safety Review

Novartis’s Gilenya Loses Market Share After Safety Review
“If they have any history of any kind of cardiac disease, we won’t consider the drug,” Vollmer said in a telephone interview. “For older patients, we’re a little bit reluctant because of the cardiac issues.”